Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement ...

Vera Therapeutics (NASDAQ:VERA – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Vera Therapeutics to post earnings of ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.

BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target ...

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price objective increased by Guggenheim from $59.00 to $61.00 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on ...

JPMorgan analyst Anupam Rama lowered the firm’s price target on Vera Therapeutics (VERA) to $71 from $77 and keeps an Overweight rating on the ...

A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website. Vera Therapeutics is a late clinical-stage ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Vera Therapeutics Inc (Symbol: VERA) entered into oversold territory, hitting an RSI reading ...